These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19668084)

  • 21. Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences.
    Mata RC; Viciana P; de Alarcón A; López-Cortés LF; Gómez-Vera J; Trastoy M; Cisneros JM
    AIDS Patient Care STDS; 2005 Sep; 19(9):550-62. PubMed ID: 16164382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.
    Murray M; Hogg RS; Lima VD; May MT; Moore DM; Abgrall S; Bruyand M; D'Arminio Monforte A; Tural C; Gill MJ; Harris RJ; Reiss P; Justice A; Kirk O; Saag M; Smith CJ; Weber R; Rockstroh J; Khaykin P; Sterne JA;
    HIV Med; 2012 Feb; 13(2):89-97. PubMed ID: 21819529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
    ; Young J; Psichogiou M; Meyer L; Ayayi S; Grabar S; Raffi F; Reiss P; Gazzard B; Sharland M; Gutierrez F; Obel N; Kirk O; Miro JM; Furrer H; Castagna A; De Wit S; Muñoz J; Kjaer J; Grarup J; Chêne G; Bucher H
    PLoS Med; 2012; 9(3):e1001194. PubMed ID: 22448150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD).
    Egger S; Petoumenos K; Kamarulzaman A; Hoy J; Sungkanuparph S; Chuah J; Falster K; Zhou J; Law MG;
    J Acquir Immune Defic Syndr; 2009 Apr; 50(5):513-20. PubMed ID: 19408354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4+ count-guided interruption of antiretroviral treatment.
    ; El-Sadr WM; Lundgren J; Neaton JD; Gordin F; Abrams D; Arduino RC; Babiker A; Burman W; Clumeck N; Cohen CJ; Cohn D; Cooper D; Darbyshire J; Emery S; Fätkenheuer G; Gazzard B; Grund B; Hoy J; Klingman K; Losso M; Markowitz N; Neuhaus J; Phillips A; Rappoport C
    N Engl J Med; 2006 Nov; 355(22):2283-96. PubMed ID: 17135583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa.
    Hoffmann CJ; Schomaker M; Fox MP; Mutevedzi P; Giddy J; Prozesky H; Wood R; Garone DB; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2013 May; 63(1):34-41. PubMed ID: 23344547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.
    Pantazis N; Touloumi G; Meyer L; Olson A; Costagliola D; Kelleher AD; Lutsar I; Chaix ML; Fisher M; Moreno S; Porter K;
    AIDS; 2016 Mar; 30(6):879-88. PubMed ID: 26636925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of effect of menopause status at initiation of first-line antiretroviral therapy on immunologic or virologic responses: a cohort study from Rio de Janeiro, Brazil.
    Calvet GA; Velasque L; Luz PM; Cardoso SW; Derrico M; Moreira RI; de Andrade AC; Cytryn A; Pires E; Veloso VG; Grinsztejn B; Friedman RK
    PLoS One; 2014; 9(2):e89299. PubMed ID: 24586673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.
    Cornell M; Schomaker M; Garone DB; Giddy J; Hoffmann CJ; Lessells R; Maskew M; Prozesky H; Wood R; Johnson LF; Egger M; Boulle A; Myer L;
    PLoS Med; 2012; 9(9):e1001304. PubMed ID: 22973181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.
    Li X; Margolick JB; Jamieson BD; Rinaldo CR; Phair JP; Jacobson LP
    J Acquir Immune Defic Syndr; 2011 Aug; 57(5):421-8. PubMed ID: 21602699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy.
    Bisson GP; Gross R; Bellamy S; Chittams J; Hislop M; Regensberg L; Frank I; Maartens G; Nachega JB
    PLoS Med; 2008 May; 5(5):e109. PubMed ID: 18494555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy.
    Pantazis N; Papastamopoulos V; Paparizos V; Metallidis S; Adamis G; Antoniadou A; Psichogiou M; Chini M; Sambatakou H; Sipsas NV; Gogos C; Chrysos G; Panagopoulos P; Katsarou O; Gikas A; Touloumi G;
    AIDS; 2019 Aug; 33(10):1645-1655. PubMed ID: 31305332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response.
    Moore DM; Hogg RS; Chan K; Tyndall M; Yip B; Montaner JS
    AIDS; 2006 Feb; 20(3):371-7. PubMed ID: 16439870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
    Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A
    BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
    O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
    Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.
    Wood E; Hogg RS; Yip B; Tyndall MW; Sherlock CH; Harrigan RP; O'Shaughnessy MV; Montaner JS
    J Acquir Immune Defic Syndr; 2002 Jun; 30(2):159-66. PubMed ID: 12045678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.
    Fox MP; Sanne IM; Conradie F; Zeinecker J; Orrell C; Ive P; Rassool M; Dehlinger M; van der Horst C; McIntyre J; Wood R
    AIDS; 2010 Aug; 24(13):2041-50. PubMed ID: 20613459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
    Davey RT; Murphy RL; Graziano FM; Boswell SL; Pavia AT; Cancio M; Nadler JP; Chaitt DG; Dewar RL; Sahner DK; Duliege AM; Capra WB; Leong WP; Giedlin MA; Lane HC; Kahn JO
    JAMA; 2000 Jul; 284(2):183-9. PubMed ID: 10889591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.
    Nachega JB; Hislop M; Dowdy DW; Chaisson RE; Regensberg L; Maartens G
    Ann Intern Med; 2007 Apr; 146(8):564-73. PubMed ID: 17438315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.